- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03561909
Kinetics of Blood Platelets Transfused to Healthy Subjects
An Open-label, Single Centre, Exploratory Trial Investigating the Kinetics of Platelets Transfused to Healthy, Male Subjects
The current phase 0 trial is preceding the phase 1/2 trial of a newly developed drug, NAITgam, for the prevention of fetal and neonatal alloimmune thrombocytopenia (FNAIT) - a rare, but potentially very severe bleeding condition in the fetus or newborn. FNAIT may occur in women whose blood platelets do not express HPA-1a. If the fetus has inherited HPA-1a from the father, the mother's immune system may be stimulated to produce HPA-1a antibodies if HPA-1a positive fetal blood platelets enter the maternal circulation during delivery. In a subsequent pregnancy, such antibodies will cross the placenta and may reduce the number of HPA-1a positive blood platelets in the fetus, which in turn may result in severe bleeding in the fetus or newborn.
The phase 1/2 study of NAITgam will examine NAITgam's ability to eliminate HPA-1a positive blood platelets that has been transfused to healthy male subjects, whose blood platelet do not express HPA-1a. The ability to quickly eliminate transfused HPA-1a positive platelets is considered as a surrogate endpoint for NAITgam's ability to prevent formation of antibodies against HPA-1a after delivery of an HPA-1a positive child.
The current phase 0 trial will examine the survival of blood platelets transfused to healthy male individuals without subsequent administration of NAITgam. The natural survival of transfused platelet, as determined in the phase 0 trial, will be compared with the survival of transfused HPA-1a positive platelets after administration of NAITgam in the phase 1/2 trial. The aim of the phase 0 trial is first, to determine the dose of blood platelet that should be transfused to the healthy subjects in the phase 1/2 trial; and secondly, to determine the optimal time point, after transfusion of platelets, for administration of NAITgam in the phase 1/2 trial.
Eight to 24 healthy male subjects will be included in the phase 0 trial. After transfusion of platelets, blood samples will be collected at regular intervals to determine the proportion of transfused blood platelets. Differences between tissue type antigens between donor and recipient will be used to determine the proportion of transfused platelets. Survival of transfused platelets will be performed by flow cytometry - a method that can be used to quantify very small proportions of cells in the blood. Fluorochrome-conjugated monoclonal antibodies against HLA-A2 and HLA-A9 will be used for flow cytometric identification the transfused platelets.
Study Overview
Status
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hessia
-
Frankfurt am main, Hessia, Germany, 60596
- Fraunhofer Institute for Molecular Biology and Applied Ecology IME
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Written informed consent must be obtained before any trial related procedures are performed
- Healthy, male subjects
- Age ≥18 and < 50 years old
- BMI < 30kg/mˆ2
- HLA-A2 and/or HLA-A9 negative
Exclusion Criteria:
- History of hypersensitivity to platelet concentrates or human plasma protein
- Subjects with known IgA deficiency and anti-IgA antibodies
- Blood donation received within 3 weeks
- Platelet counts < 150 × 10ˆ9/L or > 450 × 10ˆ9/L
- Any type of known platelet function disorder
- Treatment with non-steroidal anti-inflammatory drugs (NSAIDs, e.g. acetylsalicylic acid) or selective serotonin reuptake inhibitors within 7 days prior to Visit 1
- Chronic or ongoing active infectious disease requiring systemic treatment including, but not limited to, chronic and renal infection, chronic chest infection with bronchiectasis, and tuberculosis
- Participation in any other interventional clinical trial during the trial period
- Subjects known or suspected of not being able to comply with this trial protocol (e.g. due to alcoholism, drug dependency or psychological disorder)
- Presence of HLA-antibodies class I (MFI level > 3000)
- Signs of previous or ongoing infection with HIV and/or Hepatitis B and/or C virus
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Other: Platelet transfusion
HLA-A2 and/or HLA A9 negative healthy study subjects will be transfused with a small dose of platelets from an HLA-A2 and/or HLA-A9 positive donor.
|
Transfusion of a platelet dose from 20 × 10ˆ9 to 100 × 10ˆ9.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Terminal elimination half live
Time Frame: The terminal elimination half live of transfused platelets will be determined based on the survival of platelets within the first 5 days after trandfusion
|
Determination of the terminal elimination half live of a single platelet dose transfused to healthy male subjects
|
The terminal elimination half live of transfused platelets will be determined based on the survival of platelets within the first 5 days after trandfusion
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Cmax
Time Frame: Will be determined within the first 5 days after transfusion
|
The peak platelet concentration
|
Will be determined within the first 5 days after transfusion
|
AUC
Time Frame: Will be determined within the first 5 days after transfusion
|
The area under the platelet concentration versus time curve
|
Will be determined within the first 5 days after transfusion
|
Clearance
Time Frame: Will be determined within the first 5 days after transfusion
|
Natural clearance of platelets from the circulation
|
Will be determined within the first 5 days after transfusion
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Chair: Jens Kjeldsen-Kragh, MD, PhD, Prophylix Pharma AS
- Principal Investigator: Michaela Köhm, MD, Fraunhofer Institute for Molecular Biology and Applied Ecology IME
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- PX-0
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Fetal and Neonatal Alloimmune Thrombocytopenia
-
Rallybio IPA, LLCRecruitingFetal and Neonatal Alloimmune ThrombocytopeniaUnited States, Canada, Netherlands, Norway, United Kingdom, Sweden, Germany
-
Leiden University Medical CenterSanquin Research & Blood Bank Divisions; Landsteiner Foundation for Blood TransfusionCompletedFetal and Neonatal Alloimmune ThrombocytopeniaNetherlands
-
Assistance Publique Hopitaux De MarseilleWithdrawnNeonatal Thrombocytopenia Isoimmunization Maternal-fetalFrance
-
Leiden University Medical CenterSanquin-LUMC J.J van Rood Center for Clinical Transfusion ResearchUnknownNeurodevelopmental Abnormality | Fetal and Neonatal Alloimmune Thrombocytopenia | Long Term Adverse Effects | Intravenous Immunoglobulin Adverse ReactionNetherlands
-
Weill Medical College of Cornell UniversityColumbia University; New York Presbyterian HospitalCompletedAlloimmune Thrombocytopenia | Fetal Alloimmune ThrombocytopeniaUnited States
-
Xinqiao Hospital of ChongqingPeking University First Hospital; LanZhou University; RenJi Hospital; Qilu Hospital... and other collaboratorsUnknownNeonatal Alloimmune Thrombocytopenia
-
Sylvia ElzekUnknownThrombocytopenia Neonatal
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); Beth Israel Deaconess Medical... and other collaboratorsActive, not recruitingNeonatal ThrombocytopeniaUnited States
-
Karolinska InstitutetHarvard Medical School (HMS and HSDM); Karolinska University Hospital; National... and other collaboratorsRecruitingBleeding | Neonatal ThrombocytopeniaUnited States, Netherlands, Sweden
-
Boston Children's HospitalNational Heart, Lung, and Blood Institute (NHLBI); Beth Israel Deaconess Medical...RecruitingNeonatal ThrombocytopeniaUnited States
Clinical Trials on Platelet transfusion
-
National Institutes of Health Clinical Center (CC)Recruiting
-
Fred Hutchinson Cancer CenterNational Cancer Institute (NCI)TerminatedAcute Myeloid Leukemia | Primary Myelofibrosis | Thrombocytopenia | Acute Lymphoblastic Leukemia | Chronic Lymphocytic Leukemia | Venous Thromboembolism | Myelodysplastic Syndrome | B-Cell Non-Hodgkin Lymphoma | Hematopoietic Cell Transplantation Recipient | Chronic Myelogenous Leukemia, BCR-ABL1 Positive and other conditionsUnited States
-
University of OklahomaCompletedThrombocytopeniaUnited States
-
Technische Universität DresdenCompletedMyeloid LeukemiaGermany
-
University Hospital TuebingenWithdrawnSepsis | Thrombocytopenia
-
Sofia RamströmEnrolling by invitation
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedHematologic Diseases | Blood Transfusion | Leukemia, Myelocytic, Acute | Immunization | Blood Platelets
-
Ottawa Hospital Research InstituteCanadian Institutes of Health Research (CIHR); Canadian Blood ServicesTerminatedLeukemia | Myelodysplastic SyndromeCanada
-
M.D. Anderson Cancer CenterTerminatedLymphoma | LeukemiaUnited States
-
Susan SmythWithdrawnSepsis | ThrombocytopeniaUnited States